| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012359440 |
| P356 | DOI | 10.1007/S11886-014-0548-6 |
| P698 | PubMed publication ID | 25326731 |
| P5875 | ResearchGate publication ID | 267043713 |
| P2093 | author name string | J M Ten Berg | |
| N Bennaghmouch | |||
| W J M Dewilde | |||
| P2860 | cites work | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q22241919 |
| Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks | Q24244298 | ||
| RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome | Q24623137 | ||
| Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial | Q26248603 | ||
| Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial | Q28165358 | ||
| Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting | Q28183958 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis | Q28194233 | ||
| Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials | Q28201304 | ||
| Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting | Q28218635 | ||
| Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment | Q28219004 | ||
| Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives | Q28222158 | ||
| Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation | Q28277375 | ||
| Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
| 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association | Q29614695 | ||
| Rivaroxaban versus warfarin in nonvalvular atrial fibrillation | Q29614696 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study | Q31102731 | ||
| Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. | Q33518180 | ||
| Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. | Q45973858 | ||
| Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. | Q45995789 | ||
| Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials. | Q45997231 | ||
| Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation. | Q46001195 | ||
| Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation | Q46096675 | ||
| Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Trea | Q46300955 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective | Q50188024 | ||
| Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. | Q51041879 | ||
| Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis. | Q51800058 | ||
| Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. | Q53098597 | ||
| Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. | Q53652642 | ||
| Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | Q56620375 | ||
| Bleeding risk assessment and management in atrial fibrillation patients | Q57627129 | ||
| Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting | Q57627371 | ||
| 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary | Q61667402 | ||
| Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial | Q84062702 | ||
| A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) | Q85015607 | ||
| Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents | Q86958630 | ||
| ??? | Q22242895 | ||
| ??? | Q28217745 | ||
| ??? | Q28252529 | ||
| Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography | Q34034720 | ||
| Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial | Q34043989 | ||
| Apixaban with antiplatelet therapy after acute coronary syndrome | Q34202772 | ||
| Rivaroxaban in patients with a recent acute coronary syndrome | Q34231902 | ||
| Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials | Q34301615 | ||
| New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis | Q34331671 | ||
| A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents | Q34374902 | ||
| A population-based study of the drug interaction between proton pump inhibitors and clopidogrel | Q34603772 | ||
| Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians | Q34607441 | ||
| Clopidogrel with or without omeprazole in coronary artery disease | Q34660303 | ||
| Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. | Q34793416 | ||
| Effect of clopidogrel added to aspirin in patients with atrial fibrillation | Q34972265 | ||
| Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials | Q37350338 | ||
| Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents | Q37748327 | ||
| Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation | Q37823989 | ||
| Clopidogrel-drug interactions | Q37851658 | ||
| Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control | Q37995402 | ||
| Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials | Q38016250 | ||
| Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis | Q38049387 | ||
| Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. | Q38052502 | ||
| Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials | Q38054689 | ||
| Low-dose anticoagulation for secondary prevention in acute coronary syndrome | Q38065516 | ||
| Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation | Q38176288 | ||
| One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry | Q38437086 | ||
| Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial | Q38442153 | ||
| Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial | Q38474249 | ||
| Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study | Q38479317 | ||
| Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry | Q39986890 | ||
| Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial | Q42687692 | ||
| Radial versus femoral access for orally anticoagulated patients | Q42873141 | ||
| Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation | Q42908804 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Duration of dual antiplatelet therapy after implantation of drug-eluting stents. | Q43128835 | ||
| Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention | Q43686889 | ||
| "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment | Q43692725 | ||
| Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis | Q43920495 | ||
| Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study | Q44481393 | ||
| Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. | Q44543163 | ||
| Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. | Q45930222 | ||
| Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. | Q45962608 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 548 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | Current cardiology reports | Q26842345 |
| P1476 | title | Dual antiplatelet therapy in the anticoagulated patient undergoing percutaneous coronary intervention risks, benefits, and unanswered questions | |
| P478 | volume | 16 |
| Q36139617 | Dental extraction in patients receiving dual antiplatelet therapy | cites work | P2860 |
Search more.